DETECTION OF CELLULAR/IMMUNE RESPONSES TO MITF IN NORMAL SUBJECTS AND

检测正常受试者和受试者中对 MITF 的细胞/免疫反应

• 批准号: 7982076
• 负责人: Don J Diamond
• 金额: $ 3.36万
• 依托单位: UNIVERSITY OF SOUTHERN CALIFORNIA
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-12-01 至 2009-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7982076
• 关键词: Bioinformatics; Blood; Clinical Research; Computer Retrieval of Information on Scientific Projects Database; Disease; Flow Cytometry; Funding; Grant; Immune; Immune response; Immunotherapy; Institution; Melanoma Cell; Patients; Peptides; Proteins; Regulator Genes; Research; Research Personnel; Resistance; Resources; Role; Source; Staging; Surveys; Transcription factor genes; United States National Institutes of Health; chemotherapy; healthy volunteer; melanocyte; melanoma; transcription factor; volunteer

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. A melanocyte master regulatory gene called MITF (Micro-phthalmia-associated transcription factor) was found to be amplified in progressive melanomas. MITF amplification was more prevalent in metastatic disease and correlated with decreased overall patient survival. Since the melanoma cells with amplified MITF are highly resistant to chemotherapy, a different approach utilizing the power of immunotherapy will be enlisted to evaluate whether an alternative strategy may prove useful in therapy or as a marker for progressive melanoma. The role of the volunteers and patients will be to donate blood, which will be surveyed using peptides derived from the MITF gene that have been determined using bioinformatics approaches. These peptides will be used in flow cytometry studies to determine whether there is immune recognition of this gene product and whether the recognition is present in both healthy volunteers and melanoma patients with different stages of the disease.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 发现一种称为MITF（微邻苯二醇相关的转录因子）的黑色素细胞主调节基因在进行性黑色素瘤中被扩增。 MITF扩增在转移性疾病中更为普遍，与患者总生存期降低相关。 由于具有放大MITF的黑色素瘤细胞对化学疗法具有高度抗性，因此利用免疫疗法的其他方法将被邀请来评估替代策略是否可能在治疗中有用还是作为进行性黑色素瘤的标志物。志愿者和患者的作用将是捐赠血液，该血液将使用源自MITF基因的肽进行调查，这些肽已使用生物信息学方法确定。这些肽将用于流式细胞仪研究中，以确定该基因产物是否存在免疫识别，以及该疾病不同阶段的健康志愿者和黑色素瘤患者是否存在识别。